This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Daniel D. Gretler, MD; William J. Elliott, MD, PhD; Mauro Moscucci, MD; Rory W. Childers, MD; Michael B. Murphy, MD

Arch Intern Med. 1992;152(12):2445-2448.

Abstract
• Background.—
Electrocardiograms are routinely obtained before and during the acute treatment of hypertensive emergencies, usually to rule out "ischemic changes." Despite a few anecdotal reports of electrocardiographic changes, little is known about the incidence and significance of such changes, or their relationship to the treatment used.

Methods.—
We prospectively analyzed 12-lead electrocardiograms from 21 patients admitted for hypertensive emergencies (average blood pressure, 222±4/140±3 mm Hg). Patients were randomly assigned to treatment with sodium nitroprusside (n=11) or the dopamine receptor agonist fenoldopam mesylate (n=10). Electrocardiograms were obtained at baseline and within 30 minutes of reaching goal blood pressure (diastolic blood pressure, 100 to 110 mm Hg).

Result.—
There was no significant effect of either drug treatment on PR interval, QRS duration, QT interval, or R-wave amplitude, and no major ST-segment changes were noted. During treatment with either drug, the average T-wave amplitude decreased in all leads except aVR. New T-wave inversions in lead v4 occurred in two and four patients after fenoldopam and nitroprusside treatment, respectively. There were no clinically apparent episodes of myocardial ischemia in any patient.

Conclusions.—
Even in the absence of obvious myocardial ischemia, a decrease in T-wave amplitude, including T-wave inversion, occurs commonly during acute blood pressure reduction in hypertensive emergencies, an observation that may be explained by the accompanying acute changes in cardiac chamber volumes.

(Arch Intern Med. 1992;152:2445-2448)

Author Affiliations
From the Section of Cardiology, Department of Internal Medicine, The University of Chicago (Ill).

Footnotes
Accepted for publication April 28, 1992.

Reprint requests to Department of Pharmacology and Therapeutics, University College, Cork, Ireland (Dr Murphy).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

In vitro effects of antihypertensive drugs on thromboxane agonist (U46619)-induced vasoconstriction in human internal mammary artery
Tanaka et al.
Br J Anaesth 2004;93:257-262.
ABSTRACT | FULL TEXT  

Role of Lead aVR in Evaluation of 12-Lead Electrocardiogram
Siddiqui and Khan
ANGIOLOGY 2002;53:709-713.
ABSTRACT  

Fenoldopam -- A Selective Peripheral Dopamine-Receptor Agonist for the Treatment of Severe Hypertension
Murphy et al.
NEJM 2001;345:1548-1557.
FULL TEXT